Reveals effective characterization of N-glycopeptides in blood samples, suggesting implications for cancer diagnosis.
The analysis of N-glycopeptides using mass spectrometry comes with numerous challenges, one of which is the unique fragmentation features associated with glycopeptides. Generally, low energy collision-based fragmentation can provide valuable information by the glycan-related B- and Y-ions but often at the expense of peptide backbone coverage. On the other hand, while electron-based fragmentation methods provide good peptide backbone coverage and allow glycan localization, they do not generate sufficient structural details on the glycans by missing B- and Y-ions. Here, we systematically optimized a ZenoTOF 7600 system employing electron-activated dissociation (EAD) as an alternative electron-based fragmentation method. Combined with collision-induced dissociation (CID), hybrid fragmentation (EAciD) on N-glycopeptides generated information-rich MS² spectra that improved the identification of N-glycopeptides in complex samples. We applied this method to a small cohort of blood donors, analyzing glycopeptide-enriched blood samples of healthy donors and patients suffering from pancreatic cancer or hepatocellular carcinoma. On the ZenoTOF 7600 system, we were able to efficiently detect ∼1900 glycopeptides per sample. EAciD especially performed well in sequencing and identifying very large N-glycopeptides carrying sizable and structurally complex glycan moieties. This allowed us to observe disease-specific N-glycopeptide signatures on numerous highly abundant blood proteins, mostly related to changes in fucosylation and complex extended glycoforms.
No takes yet. Share an insight, caveat, or question.
Jager et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: